



## Health, Healthy Living and Seniors

Public Health and Primary Health Care Division  
Communicable Disease Control  
4<sup>th</sup> Floor, 300 Carlton St, Winnipeg, MB R3B 3M9  
T 204 788-6737 F 204 948-2040  
[www.manitoba.ca](http://www.manitoba.ca)

March 4, 2016

Health Care Provider:

### **URGENT ACTION REQUIRED: Menjugate Vaccine Lot 150401 Recall**

Manitoba Health Healthy Living and Seniors (MHLS) has been notified by the Public Health Agency of Canada (PHAC) that GlaxoSmithKline(GSK) has issued a voluntary recall for Menjugate vaccine lot 150401 pending investigation of three cases of anaphylaxis reported with this vaccine's use in Quebec.

MHLS has confirmed that Menjugate vaccine lot 150401 has been shipped to providers in Manitoba.

Effective immediately:

- Do not administer Menjugate vaccine lot 150401
- Check vaccine supply for Menjugate lot 150401, remove from your vaccine fridge and label 'Do Not Use'
- Return this product to the provincial vaccine warehouse using the Vaccine and Biologics Return Form (<http://www.gov.mb.ca/health/publichealth/cdc/div/docs/vbrpp.pdf>)
- Reorder your Menjugate supply using the Vaccine and Biologics Order Form (<http://www.gov.mb.ca/health/publichealth/cdc/protocol/vaccinebiologics.pdf>)

MHLS has received no reports of anaphylaxis following vaccine from this particular lot. PHAC's Canadian Adverse Events Following Immunization Surveillance System (CAEFISS) has not received any additional reports of anaphylaxis from Menjugate lot 150401.

This recall applies to Menjugate vaccine lot 150401 only. Other vaccine lots can be used, and MHLS has adequate quantities of non-impacted lots to maintain security of supply.

If you have any questions, please contact MHLS at 204-788-6737

Sincerely,

Thank you.

*"Original signed by"*

Inga Hossack, BSc.  
A/Director  
Communicable Disease Control

*"Original signed by"*

Tim Hilderman, MD FRCP  
Medical Officer of Health - Vaccines  
Communicable Disease Control